Cell and Gene Therapy Leadership Announcement
Labcorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, announces the appointment of Maryland Franklin, PhD, as Vice President and Enterprise Head of Cell & Gene Therapy (CGT) for Labcorp’s Drug Development business unit, Covance.
The appointment of Dr. Franklin continues the organization’s ongoing commitment to and investment in the people, processes and technologies developing these remarkable precision medicines. In her role, Dr. Franklin will oversee the broad array of solutions available to sponsors developing advanced therapies in order to help them reduce risks, rapidly transition programs within and between phases of development, and achieve more patient-centric experiences. To support these efforts, Dr. Franklin will further extend Covance by Labcorp’s industry leading position for proactive engagements and scientifically focused sponsor interactions.
“Dr. Franklin will also work closely with and guide our highly experienced scientists within and across the functional disciplines that sponsors need to seamlessly develop and commercialize a cell or gene therapy. Our Cell & Gene Therapy Science & Operations Services are well positioned to support sponsors’ needs throughout the drug development process with unsurpassed expertise and world-class operational facilities across the globe,” said Dr. Bill Hanlon, President, Clinical Therapeutic & Regulatory Sciences for Covance by Labcorp.
“Cell and gene therapy approaches continue to show great promise and important successes in treating a variety of diseases that range from extremely debilitating rare diseases to applications in Oncology. With several approved advanced therapies to date and many, many more in development, I’m excited and committed to helping sponsors in their mission to improve the lives of patients,” said Dr. Franklin.
Dr. Franklin previously was the Site Lead and Executive Director, Scientific Development for the Covance Ann Arbor facility (formerly MI Bioresearch) that focuses on preclinical oncology. In that role, she led the effort that positioned the site at the forefront of immuno-oncology capabilities and services, including a focus on the models and assays supporting the early development of cell therapies. Dr. Franklin has a PhD in Medical Genetics, is a co-author of more than two dozen peer–reviewed publications and has more than 20 years of academic and biopharmaceutical industry experience.
Covance by Labcorp has witnessed tremendous growth in demand for its cell and gene therapy solutions in recent years, building on our broad expertise and experience developing advanced therapies. “In the last 5 years, Covance by Labcorp has conducted more than 500 preclinical studies and nearly 100 clinical programs for cell and gene therapy candidates. Covance has also supported the development of the 3 FDA approved CAR T-cell therapies, and the 2 FDA approved gene replacement therapies,” said Dr. Steve Anderson, Chief Scientific Officer for Covance by Labcorp.